|Articles|November 25, 2011

Harmonized Culture Media for MLT

Oxoid and Remel, the world leading microbiology brands of Thermo Fisher Scientific, have introduced a complete portfolio of culture media for the microbiological examination of non-sterile pharmaceutical products, as recommended in the Harmonized Microbial Limit Tests chapters in the Ph. Eur, USP and JP.

Oxoid and Remel, the world leading microbiology brands of Thermo Fisher Scientific, have introduced a complete portfolio of culture media for the microbiological examination of non-sterile pharmaceutical products, as recommended in the Harmonized Microbial Limit Tests chapters in the Ph. Eur, USP and JP.

The fully validated portfolio (validation documents available on request) includes dehydrated culture media and prepared media for both microbial enumeration tests and specific micro-organism testing.

Rigorous quality assurance and quality control systems ensure that Oxoid and Remel media meet the technical specifications and regulatory standards that pharmaceutical microbiologists require. Carefully sourced raw materials are fully traceable. Quality control is performed quantitatively and qualitatively, using the recommended strains and incubation/temperature parameters outlined in the harmonized MLT chapters of the Ph. Eur, USP and JP. Pharmaceutical companies can therefore have complete confidence in the Oxoid and Remel portfolio.

Oxoid and Remel prepared media are produced in specialized production facilities* in the UK, Germany, USA, Canada and Australia. These units utilize state-of-the-art equipment and carefully controlled environments to ensure consistent, high-quality products made to the latest international standards. On-site inspections and audits are welcome and can be arranged through Oxoid and Remel representatives.

Find out more here.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.